Part B Coding Coach: HCPCS Q2048 or J9002 in 2013? Doxil Coding Changes Again in the New Year

Why This Topic Matters

It helps billers and coding professionals identify which 2013 HCPCS drug codes changed, which brand-name drugs were newly distinguished, and which existing codes were revised or removed. That makes it useful for organizations reporting injectable and infused drugs under Part B.

Article Sections

1. Add Another Chapter to the Doxil Story

   Discusses HCPCS changes involving a liposomal doxorubicin product and related temporary and replacement reporting codes.

2. Distinguish Erwinaze From Other Asparaginase

   Covers a new HCPCS entry for an asparaginase product and a revision to an existing asparaginase code definition.

3. Adcetris Has a New Permanent Code

   Reviews the addition of a specific code for a targeted oncology biologic and the retirement of a prior temporary code.

4. Steer Clear of Ophthalmic Mitomycin Code

   Addresses changes involving mitomycin and distinguishes an oncology-related injectable listing from an ophthalmic entry.

5. J1569 Is Now OK for Sub-Q Admin

   Summarizes revisions to immune globulin code language and the scope of administration referenced in the article.

6. J7178 Completes the Fibrinogen Transition

   Explains HCPCS deletion and replacement activity for human fibrinogen concentrate within the clotting factor code structure.

7. Look to J1741 for IV Ibuprofen

   Covers the move of intravenous ibuprofen from a temporary hospital outpatient code to a permanent J code.

8. Watch Units for Relistor

   Discusses a newly added code for methylnaltrexone and highlights unit-based reporting considerations described in the article.